腹膜透析和血液透析对终末期肾病患者心脏结构和功能的影响

doi:10.3969/j.issn.10073205.2019.01.010

摘要/Abstract

摘要： ［摘要］〓
〖HTH〗目的〖HTSS〗〖KG*2〗观察腹膜透析和血液透析对终末期肾病患者心脏结构和功能的作用，并探讨患者临床指标与心脏结构和功能的相关性。
〖HTH〗方法〖HTSS〗〖KG*2〗选择终末期肾病患者180 例，按照透析方式的不同分为腹膜透析组90例和血液透析组90例。比较2组残余尿量、血压、血脂和血液生化指标。2组在透析前后进行心脏彩色超声检查，观察其心脏室间隔厚度（interventricular septum thickness,IVST）、左心室后壁舒张期厚度（left ventricular pesterior wall diastolic thickness,LVPWDT）、左心室舒张末期内径（left ventricular enddiastolic diameter,LVEDD）、左心房前后径（left atrium diameter,LAAP）、左心室射血分数（left ventricular ejection fraction,LVEF），并计算左心室心肌重量指数（left ventricular myocardial mass index,LVMI）。将以上观察指标与LVMI进行相关分析。
〖HTH〗结果〖HTSS〗〖KG*2〗透析后，血液透析组残余尿量和总胆固醇均少于腹膜透析组，IVST、LVPWDT、LVEDD、LAAP、LVMI均大于腹膜透析组，差异有统计学意义(P＜005)。腹膜透析组平均动脉压明显比血液透析组升高，而血白蛋白含量降低，差异有统计学意义（P＜005）。终末期肾病患者心脏的LVMI与收缩压呈正相关（r=0.379，P＜005），而与残余尿量、血红蛋白和低密度脂蛋白胆固醇呈负相关（r=-0.423、-0.342、-0.289，P＜005）。
〖HTH〗结论〖HTSS〗〖KG*2〗血液透析对终末期肾病患者心脏结构和功能的影响较腹膜透析更大，腹膜透析可能是终末期肾病患者是更加理想的透析方式。

关键词: 肾病, 腹膜透析, 血液透析, 心脏结构和功能

Abstract: ［Abstract］ Objective〖HTSS〗〓To observe the effect of peritoneal dialysis and hemodialysis on the heart structure and function of the patients with endstage nephropathy, and to investigate the correlation between clinical indicators and the structure and function of the heart.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓One hundred and eighty patients with endstage renal disease were divided into 90 cases of peritoneal dialysis group and 90 cases of hemodialysis group according to different dialysis methods. The residual urine volume, blood pressure, blood lipids and blood biochemical parameters of the two groups were compared. All patients underwent cardiac color ultrasonography before and after dialysis, and interventricular septum thickness(IVST), left ventricular pesterior wall diastolic thickness(LVPWDT), left ventricular end diastolic diameter left ventricular enddiastolic diameter(LVEDD), left atrium diameter(LAAP), left ventricular ejection fraction(LVEF), and left ventricular myocardial mass index left ventricular myocardial mass index(LVMI) of two groups were observed. The relationships between above observations and LVMI were analyzed.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓After dialysis, the residual urine volume and total cholesterol in hemodialysis group were less than that in the peritoneal dialysis group. IVST, LVPWDT, LVEDD, LAAP, and LVMI in hemodialysis group were larger than the peritoneal dialysis group, differences were statistically significant(P＜005). The mean arterial pressure in the peritoneal dialysis group was significantly higher than that in the hemodialysis group, while the blood albumin content was decreased, with statistically significant differences(P＜005).The residual urine volume and mean arterial pressure were significantly different in the peritoneal dialysis group(P＜005). In patients with endstage renal disease, there was a positive correlation between LVMI and systolic pressure(r=0.379, P＜005), and a negative correlation between residual urine, hemoglobin and low density lipoprotein cholesterol(r=-0.423, -0.342, -0.289, P＜005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Hemodialysis has a greater impact on cardiac structure and function in patients with endstage renal disease than peritoneal dialysis, Peritoneal dialysis may be a more ideal method for patients with endstage renal disease.

Key words: nephrosis, peritoneal dialysis, hemodialysis, heart structure and function

卓建钦. 腹膜透析和血液透析对终末期肾病患者心脏结构和功能的影响[J]. 河北医科大学学报, doi: 10.3969/j.issn.10073205.2019.01.010.

ZHUO Jianqin. Effects of peritoneal dialysis and hemodialysis on the heart structure and function of patients with endstage renal disease[J]. Journal of Hebei Medical University, doi: 10.3969/j.issn.10073205.2019.01.010.

[1]	唐乐丽, 叶桂花. 2022年《免疫介导肾病患者接种COVID-19疫苗前景：ERA-IWG和EUVAS的共识声明》解读 [J]. 河北医科大学学报, 2023, 44(6): 621-628.
[2]	邢玉微, 孙泽楠, 柴雪姣, 位庚. 外周血miR-92b-5p与miR-148b-3p在2型糖尿病进展至糖尿病肾病中的表达及交互作用 [J]. 河北医科大学学报, 2023, 44(6): 654-659.
[3]	张楠, 莫小兰, 魏雪芹, 李三妮, 东蕾, 赵宜乐. 原发性肾病综合征患儿合并肺炎的病原学特点及抗感染药物分析 [J]. 河北医科大学学报, 2023, 44(6): 729-732.
[4]	谷梁, 马小溪. 甲状腺激素水平与糖尿病肾病患者高尿酸血症发生的相关性 [J]. 河北医科大学学报, 2023, 44(4): 407-411.
[5]	李文亚, 高颖, 汤颖, 邓雁北. 达格列净联合厄贝沙坦对糖尿病肾病患者尿ACR、肾小球滤过率、 CysC水平的影响 [J]. 河北医科大学学报, 2022, 43(8): 904-908.
[6]	姚鹏云, 龚亚萍, 高佳琪. CysC、IL-2、C3在慢性肾小球肾病患者中的水平及相关性研究 [J]. 河北医科大学学报, 2022, 43(6): 641-645,650.
[7]	姜姣姣, 邵云侠, 董雄军, 汪正翔, 朱亚宁. IRF1、IRF8水平与2型糖尿病肾病患者颈动脉粥样硬化的关系[J]. 河北医科大学学报, 2021, 42(9): 1027-1031.
[8]	王菡, 陈卫东, 丁志珍, 陈燕. 慢性肾脏病患者血清骨硬化蛋白与矿物质和骨异常的相关性研究[J]. 河北医科大学学报, 2021, 42(6): 671-675,694.
[9]	陈亚坤, 任瑞华, 王晓荣, 张春霞, 傅淑霞. 环孢素和他克莫司治疗特发性膜性肾病伴肾病综合征患者的效果及安全性[J]. 河北医科大学学报, 2021, 42(5): 525-530.
[10]	罗长志, 侯培勇, 苏奕明, 许太福. 血管腔内治疗致造影剂肾病的相关危险因素分析[J]. 河北医科大学学报, 2021, 42(5): 551-554,596.
[11]	陈静, 王茜, 王凯, 李文建, 李易明. 姜黄素通过miR-146a抑制NF-κB信号通路保护大鼠糖尿病肾病的机制研究[J]. 河北医科大学学报, 2021, 42(2): 134-139.
[12]	王欣, 雷琳, 卢彩平, 刘晨曦, 任巧华, 吴韬. 利拉鲁肽治疗超重、肥胖2型糖尿病并肾脏疾病的临床观察[J]. 河北医科大学学报, 2021, 42(12): 1401-1405.
[13]	李晓东, 李欣悦, 韩永斌, 李宝新. 糖尿病肾病高尿酸血症的危险因素研究[J]. 河北医科大学学报, 2021, 42(12): 1406-1410.
[14]	何立芳, 李青科, 马玉霞, 任平香, 阎双缓. 肾康注射液对糖尿病肾病患者肾功能及血清TNF-α、MCP-1、IL-6的影响[J]. 河北医科大学学报, 2020, 41(12): 1397-1400.
[15]	杨〓强1，瞿〓敏1*，姚忠岩1，张秀青1，李晨晨1，李〓蕾2. 针刺复合基础麻醉与单纯基础麻醉应用于腹膜透析置管手术麻醉效果的比较[J]. 河北医科大学学报, 2019, 40(8): 933-936.

腹膜透析和血液透析对终末期肾病患者心脏结构和功能的影响

Effects of peritoneal dialysis and hemodialysis on the heart structure and function of patients with endstage renal disease

HTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价